Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology (KURA) to $28 from $11 and keeps an Overweight rating on the shares. The firm cites the ziftomenib approval for the target increase.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- FDA Calendar: These Are the Upcoming FDA Drug Approvals
- Kura Oncology price target raised to $30 from $29 at BofA
- Kura Oncology price target raised to $38 from $36 at Wedbush
- Kura Oncology price target raised to $16 from $14 at UBS
- Kura Oncology’s Strategic Positioning and FDA Approval of Komzii Boosts Buy Rating